Literature DB >> 12127705

Procalcitonin as a marker of sepsis.

E D Carrol1, A P J Thomson, C A Hart.   

Abstract

Prompt diagnosis and treatment with appropriate antimicrobial chemotherapy is of paramount importance to reduce morbidity and mortality associated with sepsis. Inflammatory markers currently in use, such as C-reactive protein (CRP) do not reliably differentiate between the systemic inflammatory response and sepsis. Procalcitonin (PCT), a precursor of calcitonin, is a 116 amino acid protein that has been proposed as a marker of disease severity in conditions such as septicaemia, meningitis, pneumonia, urinary tract infection (UTI) and fungal and parasitic infection. In particular, serial measurements are useful in order to monitor response to therapy. Together with good clinical judgement and judicious use of antimicrobial agents, PCT should serve as a valuable adjunct in the diagnosis and management of sepsis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127705     DOI: 10.1016/s0924-8579(02)00047-x

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  43 in total

1.  Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome.

Authors:  R Arkader; E J Troster; M R Lopes; R R Júnior; J A Carcillo; C Leone; T S Okay
Journal:  Arch Dis Child       Date:  2005-12-02       Impact factor: 3.791

2.  Procalcitonin for antibiotic treatment in intensive care unit patients.

Authors:  Nathalie Layios; Bernard Lambermont
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

3.  Determining the Clinical Utility of an Absolute Procalcitonin Value for Predicting a Positive Culture Result.

Authors:  Erica M Caffarini; Joshua DeMott; Gourang Patel; Ishaq Lat
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  Pre-emptive antibiotic treatment vs 'standard' treatment in patients with elevated serum procalcitonin levels after elective colorectal surgery: a prospective randomised pilot study.

Authors:  Ansgar Michael Chromik; Frank Endter; Waldemar Uhl; Arnulf Thiede; Hans Bernd Reith; Ulrich Mittelkötter
Journal:  Langenbecks Arch Surg       Date:  2005-12-21       Impact factor: 3.445

5.  Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock.

Authors:  Y Heper; E H Akalin; R Mistik; S Akgöz; O Töre; G Göral; B Oral; F Budak; S Helvaci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

6.  Elevated procalcitonin as a diagnostic marker in meningococcal disease.

Authors:  G D Mills; H M Lala; M R Oehley; A B Craig; K Barratt; D Hood; C N Thornley; A Nesdale; N E Manikkam; P Reeve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

7.  A pilot study assessing the prognostic value of CK18 and nDNA biomarkers in severe sepsis patients.

Authors:  David J Moore; Alastair Greystoke; Fouziah Butt; Jens Wurthner; Jim Growcott; Andrew Hughes; Caroline Dive
Journal:  Clin Drug Investig       Date:  2012-03-01       Impact factor: 2.859

8.  Value of procalcitonin for diagnosing perioperative pneumonia, urinary infections and superficial surgical site infections in patients undergoing primary hip and knee arthroplasty.

Authors:  Lixuan Zhang; Daozhang Cai; Hanming Guo
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

9.  Circulating cytokines and procalcitonin in acute Q fever granulomatous hepatitis with poor response to antibiotic and short-course steroid therapy: a case report.

Authors:  Chung-Hsu Lai; Jiun-Nong Lin; Lin-Li Chang; Yen-Hsu Chen; Hsi-Hsun Lin
Journal:  BMC Infect Dis       Date:  2010-07-01       Impact factor: 3.090

Review 10.  Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis.

Authors:  B Rau; C M Krüger; M K Schilling
Journal:  Langenbecks Arch Surg       Date:  2004-03-06       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.